Patents by Inventor Edward J. Unsworth
Edward J. Unsworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120294870Abstract: Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.Type: ApplicationFiled: July 16, 2012Publication date: November 22, 2012Inventors: Vivian Takafuji, Xin Wei Wang, Edward J. Unsworth, Paul K. Goldsmith
-
Publication number: 20100322950Abstract: Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5 kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5 kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5 kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5 kD.Type: ApplicationFiled: August 30, 2010Publication date: December 23, 2010Inventors: VIVIAN TAKAFUJI, XIN WEI WANG, EDWARD J. UNSWORTH, PAUL K. GOLDSMITH
-
Publication number: 20100021469Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.Type: ApplicationFiled: September 29, 2009Publication date: January 28, 2010Inventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William A. Hook, Thomas Walsh, Karen Gray, Charles Macri
-
Publication number: 20090136524Abstract: Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.Type: ApplicationFiled: December 19, 2008Publication date: May 28, 2009Inventors: Vivian Takafuji, Xin Wei Wang, Edward J. Unsworth, Paul K. Goldsmith
-
Patent number: 7364719Abstract: Methods and compounds are described for regulating blood pressure in a subject. Specific embodiments are methods for reversing vasodilation of blood vessels, by administering to a subject a therapeutically effective amount peptide AM(11-22). The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock. Other specific embodiments are methods for reversing vasoconstriction of blood vessels, by administering to a subject a therapeutically effect amount of an inhibitor of AM(11-22), sufficient to reduce hypertension in the subject. Compounds and pharmaceutical compositions are also provided, as are kits.Type: GrantFiled: October 3, 2003Date of Patent: April 29, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Frank Cuttitta, Alfredo Martinez, William G. Stetler-Stevenson, Edward J. Unsworth, Juan M. Saavedra
-
Patent number: 7101548Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.Type: GrantFiled: August 16, 2001Date of Patent: September 5, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri
-
Patent number: 6802967Abstract: Liquid chromatography based on the difference of two or more kinds of separation modes, (e.g., chemical or physical properties of analytes) may improve separations when samples contain complex mixtures. In this invention, the analytes separated on the 1st analysis system (consisting of the 1st column and the 1st mobile phase) will be trapped onto individual trapping columns. Then the trapped analytes will be loaded onto the 2nd analysis system consisting of the 2nd column and the 2nd mobile phase. This invention has the trapping and loading mechanism consisting of a combination of switching valves necessary to produce the serial separations. Also this invention has the capability to affect online desalting when it is needed depending on a detector or the nature of the analyte mixture.Type: GrantFiled: March 6, 2002Date of Patent: October 12, 2004Assignees: Shimadzu Corporation, The United States of America as represented by the Department of Health and Human ServicesInventors: Junichi Masuda, Edward J. Unsworth, Jeffrey A. Kowalak, Sanford P. Markey
-
Publication number: 20030168392Abstract: Liquid chromatography based on the difference of two or more kinds of separation modes, (e.g., chemical or physical properties of analytes) may improve separations when samples contain complex mixtures. In this invention, the analytes separated on the 1st analysis system (consisting of the 1st column and the 1st mobile phase) will be trapped onto individual trapping columns. Then the trapped analytes will be loaded onto the 2nd analysis system consisting of the 2nd column and the 2nd mobile phase. This invention has the trapping and loading mechanism consisting of a combination of switching valves necessary to produce the serial separations. Also this invention has the capability to affect online desalting when it is needed depending on a detector or the nature of the analyte mixture.Type: ApplicationFiled: March 6, 2002Publication date: September 11, 2003Applicant: Shimadzu Corporation and The Government of the United States of America,Inventors: Junichi Masuda, Edward J. Unsworth, Jeffrey A. Kowalak, Sanford P. Markey
-
Publication number: 20020055615Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for Tpeptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.Type: ApplicationFiled: August 16, 2001Publication date: May 9, 2002Inventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri
-
Patent number: 6320022Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.Type: GrantFiled: February 17, 1998Date of Patent: November 20, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Frank Cutitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri